Table 3.
Basic clinical features of the enrolled cohorts.
| Characteristics | TCGA−KIRC | GSE22541 | GSE40435 | GSE53757 | EMTAB3267 | CheckMate | Miao |
|---|---|---|---|---|---|---|---|
| Number of samples | 225 | 40 | 101 | 72 | 53 | 45 | 16 |
| Treatment | − | − | − | − | Sunitinib | Nivolumab | Nivolumab |
| Gender | |||||||
| Male | 146 | 24 | 59 | − | 37 | 30 | 13 |
| Female | 79 | 16 | 42 | − | 16 | 15 | 3 |
| Age, years | |||||||
| Mean ± SD | 60.98 ± 11.41 | − | 64.12 ± 9.24 | − | 59.85 ± 8.22 | 61.80 ± 9.23 | 62.88 ± 6.82 |
| Grade | |||||||
| G1 | 4 | 22 | − | − | − | − | |
| G2 | 90 | 47 | − | − | − | − | |
| G3 | 91 | 24 | − | − | − | − | |
| G4 | 37 | 8 | − | − | − | − | |
| Unknown | 3 | ||||||
| Stage | |||||||
| I | 112 | − | − | 24 | − | − | − |
| II | 24 | − | − | 19 | − | − | − |
| III | 50 | − | − | 14 | − | − | − |
| IV | 37 | − | − | 15 | − | − | − |
| Unknown | 2 | ||||||
| Immunotherapy | |||||||
| Nonclinical benefit | − | − | − | − | − | 20 | 8 |
| Clinical benefit | − | − | − | − | − | 25 | 8 |